https://www.ema.europa.eu/en/medicines/human/EPAR/alhemo 2025 false false false Netherlands French English syndication feed summary of product characteristics package leaflet drug evaluation treatment outcome concizumab concizumab
--- https://ansm.sante.fr/tableau-acces-derogatoire/concizumab 2024 false false false France French concizumab guidelines for drug use summary of product characteristics package leaflet technical report hemophilia A hemophilia B hemorrhage adolescent
--- https://www.has-sante.fr/jcms/p_3563330/fr/alhemo-concizumab-hemophilie-a-et-b-avec-inhibiteurs 2024 false false false France Hereditary factor VIII deficiency disease with inhibitor (disorder) hemophilia A Hereditary factor IX deficiency disease with inhibitor (disorder) evaluation of the transparency committee concizumab hemophilia B
--- https://www.has-sante.fr/jcms/p_3466237/fr/alhemo-concizumab-hemophilie-a-et-b-avec-inhibiteurs 2023 false false false France antibodies, monoclonal, humanized treatment outcome insurance, health, reimbursement Hereditary factor VIII deficiency disease with inhibitor (disorder) hemophilia A hemorrhage adolescent adult Hereditary factor IX deficiency disease with inhibitor (disorder) concizumab evaluation of the transparency committee hemophilia B concizumab
--- https://ansm.sante.fr/actualites/avis-de-lansm-du-05-09-2023-sur-le-medicament-alhemo-dans-le-cadre-dune-demande-daap 2023 false false false France French drug information concizumab package leaflet summary of product characteristics